降纤酶治疗急性脑梗塞的临床再评价  

The clinical reevaluation of the treatment for acute cerebral infarction with defibrase

作　　者：于永发[1] 张玉梅[1] 吴江[1] 阎晓波[1] 张丽玲 矫毓娟[1] 焦卓敏[1] 刘旭红[1] 王维治[1] 

机构地区：[1]哈尔滨医科大学附属第二医院神经内科,黑龙江哈尔滨150086

出　　处：《哈尔滨医科大学学报》2000年第4期261-263,共3页Journal of Harbin Medical University

摘　　要：目的对国产降纤酶的疗效进行临床再评价。方法多中心双盲随机对照设计，将８０名急性脑梗塞（ＡＣＩ）患者随机分成两组，治疗组用降纤酶，对照组用安慰剂，均由多中心协作组统一提供。采用临床神经功能缺损程度评分及Ｂａｒｔｈｅｌ指数评分进行疗效判定及生活质量评估，观察副作用。结果①降纤酶组治疗后神经功能缺损程度评分减少，治疗后３、７天比治疗前有显著差异（Ｐ＜０．０５），治疗后１４天比治疗前有极显著差异（Ｐ＜０．０１），有效率为７８．５％；②经３个月追踪观察，降纤酶组Ｂａｒｔｈｅｌ指数变化率与对照组有显著差异（Ｐ＜０．００１），可显著改善患者的生活质量。③降纤酶可降低纤维蛋白原，但对ＡＣＩ患者ＷＢＣ、ＲＢＣ、ＨＢ、ＰＴ、ＡＰＴＴ、ＰＬＴ无显著影响（Ｐ＞０．０５）；不影响患者的肝肾功能。结论降纤酶治疗脑梗塞较为安全有效，值得临床推广使用。Objective To reevaluate the clinical effect of defibrase made in China.Methods To divide 80 patients with acute cerebral infarction(ACI) into two groups randomly, one group was treated with defibrase, the other was the consolation group, then evaluate the patients, life quality and the side-effect by clinical neurological functional deficiency score and Barthel score.Results ①The treated group got less score of neurological deficiency,there was a difference in the deficiency score on the 3rd and 7th day(p < 0.05),on the 14th day there was significant difference (P < 0.01), and the efficiency was 78 .5%;②After three months of observa- tion,the change rate of Barthel in the defibrase -treating group was different obviously from the control group (P < 0.001),and the life quality of the patients in the defibrase treating group was greatly improved.③The defibrase decreased fibrinogen, but the count of WBC.RBC.HB.PT.APTT.PLT were not affected (P > 0.05) and the functions of liver and kidney were not affected. Conclusion The treatment of defibrase for ACI is highly safe and effective, it is worth popularizing in clinical application.

关 键 词：降纤酶 急性脑梗塞 药物疗法 疗效 

分 类 号：R743.330.5[医药卫生—神经病学与精神病学] R973.2[医药卫生—临床医学]